Scientists Discover Brain Cells That Aid Brain Cancer Development
Canadian scientists have made an unexpected finding about glioblastoma, one of the deadliest and hardest-to-treat forms of brain cancer. Cells previously regarded as passive support structures in healthy brain tissue have been found to actively fuel tumor growth through signaling that boosts cancer cell function.
The discovery also points toward a drug already in wide clinical use that may be capable of interrupting that process. Both findings represent meaningful advances in a field that has seen very limited therapeutic progress over several decades.
Glioblastoma carries one of oncology’s bleakest prognoses, with survival following diagnosis typically measured in months rather than years. Patients have access to very few effective treatment options, and the outlook has changed little over recent decades. Rather than operating as a self-contained mass, glioblastoma depends heavily on support from surrounding brain tissue. Identifying which neighboring cells enable that support has long been a difficult research problem.
The study, published in Neuron and led by teams at McMaster University and Toronto’s Hospital for Sick Children, examined a cell type called oligodendrocytes. In healthy tissue, these cells maintain protective coatings around nerve fibers (myelin sheaths), supporting normal neural transmission throughout the brain.
Investigators found that oligodendrocytes can be recruited by glioblastoma, fundamentally shifting their role to produce pro-tumor signals rather than performing their normal protective function. When investigators disrupted that pathway in controlled laboratory settings, tumor development slowed markedly, revealing how much the cancer depends on this cellular relationship.
A receptor designated CCR5 sits at the center of the identified pathway. Maraviroc, an HIV medication that already holds regulatory approval and a well-documented safety profile, acts directly on that receptor. Because the drug’s clinical properties are well understood, redirecting it toward glioblastoma research is considerably faster than developing a new compound entirely.
For patients whose diagnosis comes with a narrow timeline, that speed differential is not a minor consideration. Sheila Singh, co-senior author and a surgery professor at McMaster, frames glioblastoma as a cellular ecosystem in which different populations communicate and cooperate to sustain tumor growth.
Singh contends that probing that communication network has revealed a point of weakness that an approved medication may be able to reach. Jason Moffat, co-senior author and head of Genetics and Genome Biology at SickKids, regards the tumor’s internal environment as more active and complex than the field had understood, and views the CCR5 pathway as a credible candidate for clinical exploration.
This study extends a 2024 paper by the same research groups, published in Nature Medicine, which showed that glioblastoma can exploit molecular channels that serve developmental functions in healthy brains. Taken together, the two bodies of work suggest that severing the cellular communication a tumor depends on for its survival, rather than targeting malignant cells in isolation, may offer a more durable and, hopefully, more effective route against a cancer that has long resisted conventional treatment.
The rush to develop effective therapies against glioblastoma is gaining momentum, and entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are working tirelessly to bring to market new treatments that move the dial in the fight against this deadly type of brain cancer. As more insights about what drives this cancer come to light, the outlook for the commercialization of novel treatments keeps improving.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
Canadian scientists have made an unexpected finding about glioblastoma, one of the deadliest and hardest-to-treat forms of brain cancer. Cells previously regarded as passive support structures in healthy brain tissue have been found to actively fuel tumor growth through signaling that boosts cancer cell function.
The discovery also points toward a drug already in wide clinical use that may be capable of interrupting that process. Both findings represent meaningful advances in a field that has seen very limited therapeutic progress over several decades.
Glioblastoma carries one of oncology’s bleakest prognoses, with survival following diagnosis typically measured in months rather than years. Patients have access to very few effective treatment options, and the outlook has changed little over recent decades. Rather than operating as a self-contained mass, glioblastoma depends heavily on support from surrounding brain tissue. Identifying which neighboring cells enable that support has long been a difficult research problem.
The study, published in Neuron and led by teams at McMaster University and Toronto’s Hospital for Sick Children, examined a cell type called oligodendrocytes. In healthy tissue, these cells maintain protective coatings around nerve fibers (myelin sheaths), supporting normal neural transmission throughout the brain.
Investigators found that oligodendrocytes can be recruited by glioblastoma, fundamentally shifting their role to produce pro-tumor signals rather than performing their normal protective function. When investigators disrupted that pathway in controlled laboratory settings, tumor development slowed markedly, revealing how much the cancer depends on this cellular relationship.
A receptor designated CCR5 sits at the center of the identified pathway. Maraviroc, an HIV medication that already holds regulatory approval and a well-documented safety profile, acts directly on that receptor. Because the drug’s clinical properties are well understood, redirecting it toward glioblastoma research is considerably faster than developing a new compound entirely.
For patients whose diagnosis comes with a narrow timeline, that speed differential is not a minor consideration. Sheila Singh, co-senior author and a surgery professor at McMaster, frames glioblastoma as a cellular ecosystem in which different populations communicate and cooperate to sustain tumor growth.
Singh contends that probing that communication network has revealed a point of weakness that an approved medication may be able to reach. Jason Moffat, co-senior author and head of Genetics and Genome Biology at SickKids, regards the tumor’s internal environment as more active and complex than the field had understood, and views the CCR5 pathway as a credible candidate for clinical exploration.
This study extends a 2024 paper by the same research groups, published in Nature Medicine, which showed that glioblastoma can exploit molecular channels that serve developmental functions in healthy brains. Taken together, the two bodies of work suggest that severing the cellular communication a tumor depends on for its survival, rather than targeting malignant cells in isolation, may offer a more durable and, hopefully, more effective route against a cancer that has long resisted conventional treatment.
The rush to develop effective therapies against glioblastoma is gaining momentum, and entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are working tirelessly to bring to market new treatments that move the dial in the fight against this deadly type of brain cancer. As more insights about what drives this cancer come to light, the outlook for the commercialization of novel treatments keeps improving.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
